Abstract
Our recent studies of microRNA (miRNA) expression signatures demonstrated that the epithelial–mesenchymal transition (EMT)-related microRNA-200 family (miR-200s: miR-200a/b/c, miR-141 and miR-429) were significantly downregulated in renal cell carcinoma (RCC) and putative tumor-suppressive miRNAs in RCC. In this study, our aim was to investigate the functional significance of the miR-200s in cancer cells and to identify novel miR-200s-regulated molecular targets and pathways in RCC. Expression levels of all the miR-200s members were significantly downregulated in human RCC tissues compared with normal renal tissues. Restoration of mature miR-200s in RCC cell line resulted in significant inhibition of cell proliferation and migration, suggesting that miR-200s function as tumor suppressors in RCC. Furthermore, we utilized gene expression analysis and in silico database analysis to identify miR-200s-regulated molecular targets and pathways in RCC. The miR-200s was categorized into two groups, according to their seed sequences, miR-200b/c/429 and miR-200a/141. Our data demonstrated that the ‘Focal adhesion’ and ‘ErbB signaling’ pathways were significantly regulated by miR-200b/c/429 and miR-200a/141, respectively. The identification of novel tumor-suppressive miR-200s-regulated molecular targets and pathways has provided new insights into RCC oncogenesis and metastasis.
Similar content being viewed by others
Introduction
Renal cell carcinoma (RCC) is the most common neoplasm of the adult kidney, and the incidence and mortality rates of RCC are increasing at a rate of 2–3% per decade.1 Although surgery is often curative for localized disease, a significant percentage of these patients develop relapses or metastatic disease, which are associated with poor prognosis. The 5-year survival rate of advanced stage of RCC is very poor (5–10%) because of recurrence or distant metastasis.2 To improve treatment of RCC, targeted molecular therapies that have been developed are currently being widely used for patients with metastatic or recurrent RCC. However, these targeted therapies are insufficient for patients who have relapsed or have metastatic disease.3 Therefore, it is important to understand the molecular mechanisms underlying RCC recurrence and metastasis, as this knowledge may be used to help improve RCC treatment.
The discovery of non-coding RNAs in the human genome was an important conceptual breakthrough in the post-genome sequencing era.4 Improved understanding of non-coding RNAs is necessary for continued progress in cancer research. MicroRNAs (miRNAs) are a class of small non-coding RNA molecules of 19–22 nucleotides that regulate protein-coding gene expression by repressing translation or cleaving RNA transcripts in a sequence-specific manner.5 A growing body of evidence suggests that miRNAs are aberrantly expressed in several types of human cancer, and that they have significant roles in the initiation, progression and metastasis of human cancers.6
It is believed that normal regulatory mechanisms can be disrupted by aberrant expression of tumor-suppressive or oncogenic miRNAs in cancer cells. Thus, identification of aberrantly expressed miRNAs is an important step in elucidating miRNA-mediated oncogenic pathways.
On the basis of recent reports describing miRNA signatures, several downregulated miRNAs have been identified. Here, we analyzed the miRNA expression signatures published in the literature to identify miRNA candidates involved in RCC.7, 8, 9, 10, 11, 12, 13, 14, 15, 16 We chose to focus on the miR-200s (miR-200a/b/c, miR-141 and miR-429), which is frequently downregulated in clinical specimens from RCC patients.
Our recent studies of miRNA expression signatures also demonstrated that the epithelial–mesenchymal transition (EMT)-related miR-200s members were significantly downregulated in RCC.8 The initial steps of invasion and metastasis involve cellular changes consistent with EMT, which is associated with a loss of epithelial characteristics; such as, the intercellular adhesion protein E-cadherin and an apical–basal polarity, and an acquisition of mesenchymal markers; such as, vimentin, collagen, fibronectin, and the E-cadherin transcriptional repressors; such as ZEB1 and ZEB2.17, 18 The miR-200s has been established as an important regulator of tumor invasion and metastasis through its targeting of ZEB1 and ZEB2.19 To date, molecular pathways regulated by the miR-200s has not been fully investigated in RCC. Greater understanding of the molecular pathways regulated by the miR-200s could lead to the development of better prognostic, diagnostic and therapeutic interventions for RCC.
The aim of this study was to investigate the functional significance of the miR-200s members and to identify the molecular targets and pathways regulated by the miR-200s members in RCC cells. The results here identified several cancer-related genes and pathways, including ‘Focal adhesion’ and ‘ErbB signaling’ pathways, as targets of the miR-200s members. These novel miR-200s-regulated signaling pathways and targeted genes provide new insights into the mechanisms of RCC oncogenesis and suggest novel therapeutic strategies for treatment of this disease.
Materials and methods
Selection of aberrantly expressed miRNAs by RCC miRNA expression signatures
We searched PubMed for publications on RCC miRNA signatures using the keywords renal cell carcinoma, kidney cancer and miRNA on 23 July 2012. We selected articles in English in which the scientific detail and reporting were sufficient to enable our understanding and that presented novel findings. Our previous miRNA expression signature study was included in the selected articles.8 We hypothesized that frequently observed low expression of miRNAs are involved in the progression and metastasis of RCC. On the basis of this point, we quantified the number of times that specific downregulated miRNAs appeared in expression signatures.
Clinical specimens and cell culture
A total of 29 clear-cell RCC and 27 normal kidney specimens were collected from patients who had undergone radical nephrectomies at Kagoshima University Hospital. Patient characteristics and representative pathological features are shown in Supplementary Table 1. The samples were processed and stored in RNAlater (Qiagen, Valencia, CA, USA) at 4 °C until RNA extraction. These specimens were staged according to the American Joint Committee on Cancer-Union Internationale Contre le Cancer tumour-node-metastasis classification and histologically graded.20 This study was approved by the Bioethics Committee of Kagoshima University, with written prior informed consent and approval given by the patients.
Cell culture and RNA extraction
Human RCC cell line, Caki-1, obtained from the American Type Culture Collection (Manassas, VA, USA), was derived from skin metastasis. Therefore, the results from analyses might be more plausible to understand the EMT-related genes and pathways than using other cell lines. The cell line was incubated in RPMI-1640 medium with 10% fetal bovine serum and maintained in a humidified incubator (5% CO2) at 37 °C. Total RNA was extracted, as described previously.8
Quantitative real-time RT-PCR
TaqMan probes and primers for ZEB1 (P/N: Hs00232783_m1; Applied Biosystems, Foster City, CA, USA), ZEB2 (P/N: Hs00207691_m1; Applied Biosystems) and CDH1 (E-cadherin, P/N: Hs01023894_m1; Applied Biosystems) were assay-on-demand gene expression products. All reactions were performed in duplicate and a negative control lacking cDNA was included. We followed the manufacturer’s protocol for polymerase chain reaction (PCR) conditions. Stem-loop reverse transcription (RT)-PCR (TaqMan MiRNA Assays; Assay ID: 000502 for miR-200a, 002251 for miR-200b, 002300 for miR-200c, 000463 for miR-141 and 001024 for miR-429; Applied Biosystems) was used to quantify miRNAs according to previously published conditions.21 To normalize the data for quantification of the miRNAs, we used human RNU48 (P/N: 001006; Applied Biosystems), and the delta–delta Ct method was used to calculate the fold-change.
Mature miRNA transfection
As described elsewhere,21 the RCC cell lines were transfected with Lipofectamine RNAiMAX transfection reagent (Invitrogen, Carlsbad, CA, USA) and Opti-MEM (Invitrogen) with 10 nM mature miRNA molecules (hsa-miR-200a for PM10991, hsa-miR-200b for PM10492, hsa-miR-200c for PM11714, hsa-miR-141 for PM10860 and hsa-miR-429 for PM10221). Negative control miRNA (CN-002000-01-05; Thermo Fisher Scientific, Waltham, MA, USA) were used in the gain-of-function experiments. We evaluated the transfection efficiency of the miRNAs in RCC cell lines based on the downregulation of mRNA expression levels of protein tyrosine kinase 9 (alias twinfilin: TWF1) after miR-1 transfection as described previously.22 Cells were seeded in six-well plates for wound-healing assays (20 × 104 cells per well) and in 96-well plates for XTT (2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide)) assays (3000 per well).
Cell proliferation and migration assays
Cell proliferation was determined with an XTT assay according to the manufacturer’s instructions (Roche Applied Science, Tokyo, Japan) 72 h after transfection. Cell migration activity was evaluated with a wound-healing assay. Cells were seeded in six-well dishes, and the cell monolayer was scraped using a P-20 micropipette tip. The initial gap length (0 h) and the residual gap length 24 h after wounding were calculated from photomicrographs. All experiments were performed in triplicate.
Identification of significantly enriched signaling pathways of the miR-200s members using oligo-microarray and in silico analysis
Oligo-microarray Human 44K (Agilent Technologies, Santa Clara, CA, USA) was used for expression profiling in each miR-200s family-transfected Caki-1 cell in comparison with miR-negative control transfectants, as described previously.23 Briefly, the hybridization and washing steps were performed in accordance with the manufacturer’s instructions. The arrays were scanned using a Packard GSI Lumonics ScanArray 4000 (Perkin-Elmer, Boston, MA, USA). The data obtained were analyzed with the DNASIS array software (Hitachi Software Engineering, Tokyo, Japan), which converted the signal intensity for each spot into text format. The log 2 ratios of the median subtracted background intensity were analyzed. Data from each microarray study were normalized by global normalization.
Their predicted target genes and their miRNA binding site seed regions were investigated using TargetScan (http://www.targetscan.org/). The sequences of the predicted mature miRNAs were confirmed using miRBase (release 19.0, August 2012; http://www.mirbase.org/).
To identify signaling pathways regulated by the miR-200 family in RCC, upregulated genes that were targeted by these miRNAs were analyzed in the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway categories using the GENECODIS program (http://genecodis.cnb.csic.es/).
Statistical analysis
The relationships between two variables and the numerical values obtained by real-time RT-PCR were analyzed using the Mann–Whitney U-test. The relationships among three variables and the numerical values were analyzed using the Bonferroni-adjusted Mann–Whitney U-test. Spearman’s rank test was used to evaluate the relationships among the relative expression levels of the miR-200s family. All statistical analyses were performed using the Expert StatView analysis software (version 4; SAS Institute Inc., Cary, NC, USA). In the comparison among six variables, a non-adjusted statistical level of significance of P<0.05 corresponds to a Bonferroni-adjusted level of P<0.0033.
Results
Aberrantly expressed miRNAs based on the RCC expression signatures
In this study, we listed 10 miRNA expression signatures of RCC based on results of database search.7, 8, 9, 10, 11, 12, 13, 14, 15, 16 We quantified the number of times that specific downregulated miRNAs appeared (Supplementary Table 2 and summarized in Table 1). Detailed information about miRNA expression signatures; such as, sample numbers and the result of each study, was shown in Supplementary Table 2. We recognized that miR-200b, miR-200c, miR-141 and miR-429 were the most frequently downregulated miRNAs (Table 1), and miR-200a was also downregulated in RCC signatures (5 of 10 signatures). Thus, we focused on the miR-200s members and investigated the functional significance and molecular pathways regulated by the miR-200s.
The miR-200s members are clustered on two different chromosomal regions; miR-200b, miR-200a and miR-429 are located on chromosome 1p36.33, whereas miR-200c and miR-141 are on the chromosome 12 p13.31 (Figure 1Aa). The miR-200s can also be classified, according to their seed sequence arrangement, into two groups: miR-200b/c/429 and miR-200a/141 (Figure 1Ab).
Expression levels of miR-200s in clinical RCC specimens and the Caki-1 RCC cell line
We evaluated expression levels of the miR-200s members in clinical RCCs (n=29), in normal specimens (n=27) and in the Caki-1 RCC cell line. Quantitative stem-loop RT-PCR demonstrated that the expression levels of miR-200b/miR-200a/miR-429 were significantly lower in clinical RCC specimens and in Caki-1 compared with pathologically normal tissues (each, P<0.0001; Figure 1B, upper). Furthermore, there were significant positive correlations between the expression levels of those clustered miRNAs (each, P<0.0001; Figure 1B, lower). The same results were obtained for miR-200c and miR-141 (P<0.0001, each; Figure 1C).
There was no significant relationship between the clinicopathological parameters and the expression levels of the miR-200s in this study (data not shown).
EMT-related gene expression in miR-200s-transfected Caki-1 RCC cell line
To select RCC cell lines suitable for the analysis, we evaluated the mRNA expression levels of EMT-associated genes, ZEB1, ZEB2 and CDH1, in miR-200s-transfected RCC cell lines (Caki-1, Caki-2 and ACHN). Quantitative real-time RT-PCR analysis showed that the mRNA expression levels of ZEB1 and ZEB2 were significantly downregulated in Caki-1 cells compared with control (P<0.0001, each; Figure 2a). In addition, the mRNA expression levels of CDH1 were significantly upregulated in miR-200b, miR-200c and miR-429 transfected cells compared with the miR-control transfectant (P<0.0001, each). There were trends but no significant differences in CDH1 mRNA expression in the miR-200a and miR-141-transfected Caki-1 cells (P=0.0047 and 0.0099, respectively). Other cell lines (Caki-2 and ACHN) were not suitable for the analysis because irregular expression of EMT-related genes were detected in those cell lines (data not shown).
Effect of miR-200s restoration on Caki-1 cell proliferation and migration
We performed gain-of-function studies using a Caki-1 cell line that had been transfected with mature miR-200s. The XTT assay demonstrated that cell proliferation was significantly suppressed in each miR-200s transfectant compared with the miR-control transfectant (P<0.0001 each; Figure 2b, upper). The wound-healing assay demonstrated that significant inhibition of cell migration occurred in each miR-200s member transfectant, except for miR-200a-transfected cells (P<0.001 each; Figure 2b, lower). There was a trend but no significant difference in the miR-200a-transfected Caki-1 cell (P=0.043). These results suggest that the miR-200s has an important role in tumor suppression by downregulating oncogenic genes.
Identification of miR-200s-regulated target genes and molecular pathways in RCC
We performed oligo-microarray analysis and in silico analysis (Figure 3). We first performed oligo-microarray using miR-200s-transfected Caki-1 cells and found a total of 1438 downregulated genes in miR-200b/miR-200c/miR-429-transfected cells and 1050 downregulated genes in miR-200a/miR-141-transfected cells compared with miR-control transfectants. Among the genes above, TargetScan database implied that 689 and 451 genes had predicted binding sites for miR-200b/miR-200c/miR-429 and miR-200a/miR-141, respectively.
To investigate the expression status of these genes in RCC clinical specimens, we examined gene expression profiles in the GEO database (accession numbers: GSE36895 and GSE22541). Among the candidate genes, 186 genes identified in miR-200b/miR-200c/miR-429 transfection and 108 genes identified in miR-200a/miR-141 transfection were actually upregulated in 53 RCC specimens compared with 23 non-cancerous kidney tissues (Tables 2a and b and Supplementary Tables 3a and b). These genes were assigned KEGG annotations by the GENECODIS program, resulting in 28 significantly enriched signaling pathways for miR-200b/miR-200c/miR-429 and 23 significantly enriched signaling pathways for miR-200a/miR-141 (Tables 3a and b, respectively, P<0.0001).
Discussion
In this study, we analyzed aberrantly expressed miRNAs in RCC, based on published data on miRNA expression signatures, including those from our recently published miRNA signature studies.8 Members of the EMT-related miR-200s have been frequently observed to be downregulated in RCC signatures, suggesting that these miRNAs function as tumor suppressors in RCC. The miR-200s members form clustered miRNAs in two different human chromosome regions; miR-200b, miR-200a and miR-429 are located on chromosome 1p36.33, whereas miR-200c and miR-141 are on the chromosome 12 p13. A previous study demonstrated that loss of 1p36 was observed in 14% of clear-cell RCCs, whereas gain of 12p13.31 was in 19% of them.24 Elucidation of the molecular mechanisms of the silencing of miR-200s expression in RCC cells will be necessary in future.
Downregulation of the miR-200s members has been reported in several cancers; such as, those of breast, liver and ovary.19, 25, 26 We also found significant low expression levels of miR-200s miRNAs in clinical RCC specimens in comparison with adjacent normal tissues. However, there was no significant relationship between the miRNA expression and clinicopathological parameters, including tumor stage, tumor grade or patient’s prognosis. Our cohort was too small and the follow-up period was too short to evaluate the relationship between them.
EMT is an important step in cancer cell invasion and metastasis and may be triggered by a number of factors, including transforming growth factors.19 It has been reported that the miR-200s regulates EMT-activating transcription factors (ZEB1 and ZEB2) and is silenced in mesenchymal-like cancer cells by TGF-β.19 A recent study demonstrated that the miR-200s members are transactivated by p53, and p53-regulated miRNAs prevented EMT by targeting ZEB1 and ZEB2 expression.27 Thus, the miR-200s family, as a new member of the p53 regulatory network, contributes to cancer cell invasion and metastasis by regulating the EMT process in human cancer.
We believed that analysis of miR-200s-regulated target genes and pathways could lead to discoveries of new molecular mechanisms in RCC recurrence and metastasis. Accordingly, we utilized the gene expression data from Caki-1 cells transfected with each miR-200s member. In this study, we categorized two groups according to their seed sequences. A total of 186 and 108 genes were listed as candidate oncogenic genes regulated by the miR-200b/miR-200c/miR-429 and miR-200a/miR-141, respectively.
We found the candidate target gene, parathyroid hormone-like hormone (PTHLH), to be the most upregulated in RCC clinical specimens and to have putative miR-200s binding sites in the 3′-untranslated region. PTHLH is a member of the parathyroid hormone family secreted factor expressed in normal tissues and is correlated with a wide range of developmental and physiological processes.28 Interestingly, overexpression of PTHLH was reported in several types of cancer,29, 30, 31, 32, 33 and circulating levels of PTHLH generally correlated with advanced stage of human cancers.32, 34, 35, 36, 37, 38, 39 A recent study demonstrated that PTHLH contributed to breast cancer growth and metastasis through its effects on several crucial signaling molecules; such as, Akt and chemokine receptor.28 Thus, the list of genes identified in our screen might be effective for searching oncogenic genes that participate in recurrence and metastasis of RCC.
Furthermore, we categorized these candidate genes into known molecular pathways using KEGG pathways; a total of 28 and 23 pathways were identified as significant miR-200b/miR-200c/miR-429- and miR-200a/miR-141-regulated pathways, respectively. All selected genes were upregulated in RCC clinical specimens by the GEO database. The ‘Focal adhesion’ and ‘ErbB signaling’ pathways were the most significantly enriched of the miR-200b/miR-200c/miR-429-regulated pathways. There were nine genes in the ‘Focal adhesion’ pathway (ITGA1, ITGA4, LAMC1, COL5A2, CAV1, PAK2, RAPGEF1, CRKL and FN1) and six genes in the ‘ErbB signaling’ pathway (RPS6KB1, PLCG1, MYC, PAK2, CBL and CRKL). Among these, fibronectin 1 (FN1), phospholipase C, gamma 1 (PLCG1) and v-myc myelocytomatosis viral oncogene homolog (MYC) have been reported to be directly regulated by miR-200b/miR-200c/miR-429 in human cancer.40, 41, 42 The ‘ErbB signaling’ pathway was also the most significantly enriched pathway in miR-200a/miR-141-regulated pathways. There were seven genes identified in this pathway (GRB2, ABL2, NCK1, CDKN1A, EGFR, STAT5B and CBL), and signal transducer and activator of transcription 5B (STAT5B) have also been reported to be directly regulated by miR-200a.43
As miRNAs are unique in their ability to regulate many protein coding genes, reduced expression of tumor-suppressing miRNAs may cause overexpression of oncogenes in cancer cells. It is very attractive to grasp the tumor-suppressing miRNAs regulated all molecular targets as cancer pathways. Here, we have described pathways mediated by the tumor-suppressing miR-200s members that provide greater insight into RCC and may offer novel therapeutic targets.
In conclusion, EMT-related miR-200s were frequently downregulated in clinical RCC, and they may function as tumor suppressors through targeting several cancer-related genes and pathways. The data from this study may provide a potentially effective and promising strategy for miRNA-associated evidence-based treatment of RCC.
Accession codes
References
Gupta, K., Miller, J. D., Li, J. Z., Russell, M. W. & Charbonneau, C. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat. Rev. 34, 193–205 (2008).
Hadoux, J., Vignot, S. & De La Motte Rouge, T. Renal cell carcinoma: focus on safety and efficacy of temsirolimus. Clin. Med. Insights Oncol. 4, 143–154 (2010).
Margulis, V., Master, V. A., Cost, N. G., Leibovich, B. C., Joniau, S., Kuczyk, M. et al. International consultation on urologic diseases and the European Association of Urology international consultation on locally advanced renal cell carcinoma. Eur. Urol. 60, 673–683 (2011).
Carthew, R. W. & Sontheimer, E. J. Origins and mechanisms of miRNAs and siRNAs. Cell 136, 642–655 (2009).
Bartel, D. P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116, 281–297 (2004).
Calin, G. A. & Croce, C. M. MicroRNA signature in human cancers. Nat. Rev. Cancer 6, 857–866 (2006).
Wu, X., Weng, L., Li, X., Guo, C., Pal, S. K., Jin, J. M. et al. Identification of a 4-microRNA signature for clear cell renal cell carcinoma metastasis and prognosis. PLoS One 7, e35661 (2012).
Hidaka, H., Seki, N., Yoshino, H., Yamasaki, T., Yamada, Y., Nohata, N. et al. Tumor suppressive microRNA-1285 regulates novel molecular targets: aberrant expression and functional significance in renal cell carcinoma. Oncotarget 3, 44–57 (2012).
Wulfken, L. M., Moritz, R., Ohlmann, C., Holdenrieder, S., Jung, V., Becker, F. et al. MicroRNAs in renal cell carcinoma: diagnostic implications of serum miR-1233 levels. PLoS One 6, e25787 (2011).
White, N. M., Bao, T. T., Grigull, J., Youssef, Y. M., Girgis, A., Diamandis, M. et al. miRNA profiling for clear cell renal cell carcinoma: biomarker discovery and identification of potential controls and consequences of miRNA dysregulation. J. Urol. 186, 1077–1083 (2011).
Weng, L., Wu, X., Gao, H., Mu, B., Li, X., Wang, J. H. et al. MicroRNA profiling of clear cell renal cell carcinoma by whole-genome small RNA deep sequencing of paired frozen and formalin-fixed, paraffin-embedded tissue specimens. J. Pathol. 222, 41–51 (2010).
Liu, H., Brannon, A. R., Reddy, A. R., Alexe, G., Seiler, M. W., Arreola, A. et al. Identifying mRNA targets of microRNA dysregulated in cancer: with application to clear cell renal cell carcinoma. BMC Syst. Biol. 4, 51 (2010).
Juan, D., Alexe, G., Antes, T., Liu, H., Madabhushi, A., Delisi, C. et al. Identification of a microRNA panel for clear-cell kidney cancer. Urology 75, 835–841 (2010).
Chow, T. F., Youssef, Y. M., Lianidou, E., Romaschin, A. D., Honey, R. J., Stewart, R. et al. Differential expression profiling of microRNAs and their potential involvement in renal cell carcinoma pathogenesis. Clin. Biochem. 43, 150–158 (2010).
Jung, M., Mollenkopf, H. J., Grimm, C., Wagner, I., Albrecht, M., Waller, T. et al. MicroRNA profiling of clear cell renal cell cancer identifies a robust signature to define renal malignancy. J. Cell. Mol. Med. 13, 3918–3928 (2009).
Nakada, C., Matsuura, K., Tsukamoto, Y., Tanigawa, M., Yoshimoto, T., Narimatsu, T. et al. Genome-wide microRNA expression profiling in renal cell carcinoma: significant down-regulation of miR-141 and miR-200c. J. Pathol. 216, 418–427 (2008).
Huber, M. A., Kraut, N. & Beug, H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr. Opin. Cell. Biol. 17, 548–558 (2005).
Xu, J., Lamouille, S. & Derynck, R. TGF-beta-induced epithelial to mesenchymal transition. Cell Res. 19, 156–172 (2009).
Gregory, P. A., Bert, A. G., Paterson, E. L., Barry, S. C., Tsykin, A., Farshid, G. et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat. Cell. Biol. 10, 593–601 (2008).
Sobin, L. H., Gospodarowicz, M. K. & Wittenkind, C. TNM Classification of Malignant Tumours, 7th ed. International Union Against Cancer 255–257 (Wiley-Liss: New York, NY, USA, 2009).
Nohata, N., Hanazawa, T., Kikkawa, N., Mutallip, M., Fujimaru, L., Yoshino, H. et al. Caveolin-1 mediates tumor cell migration and invasion and its regulation by miR-133a in head and neck squamous cell carcinoma. Int. J. Oncol. 38, 209–217 (2011).
Kawakami, K., Enokida, H., Chiyomaru, T., Tatarano, S., Yoshino, H., Kagara, I. et al. The functional significance of MiR-1 and miR-133a in renal cell carcinoma. Eur. J. Cancer 48, 827–836 (2012).
Sugimoto, T., Seki, N., Shimizu, S., Kikkawa, N., Tsukada, J., Shimada, H. et al. The galanin signaling cascade is a candidate pathway regulating oncogenesis in human squamous cell carcinoma. Genes Chromosomes Cancer 48, 132–142 (2009).
Girgis, A. H., Iakovlev, V. V., Beheshti, B., Bayani, J., Squire, J. A., Bui, A. et al. Multilevel whole-genome analysis reveals candidate biomarkers in clear cell renal cell carcinoma. Cancer Res. 72, 5273–5284 (2012).
Ladeiro, Y., Couchy, G., Balabaud, C., Bioulac-Sage, P., Pelletier, L. & Rebouissou, S. MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology 47, 1955–1963 (2008).
Dahiya, N., Sherman-Baust, C. A., Wang, T. L., Davidson, B., Shih, I. e. M. & Zhang, Y. MicroRNA expression and identification of putative miRNA targets in ovarian cancer. PLoS One 18, e2436 (2008).
Kim, T., Veronese, A., Pichiorri, F., Lee, T. J., Jeon, Y. J., Volinia, S. et al. P53 regulates epithelial–mesenchymal transition through microRNAs targeting ZEB1 and ZEB2. J. Exp. Med. 208, 875–883 (2011).
Li, J., Karaplis, A. C., Huang, D. C., Siegel, P. M., Camirand, A. & Yang, X. F. PTHrP drives breast tumor initiation, progression, and metastasis in mice and is a potential therapy target. J. Clin. Invest. 121, 4655–4669 (2011).
Nishigaki, Y., Ohsaki, Y., Toyoshima, E. & Kikuchi, K. Increased serum and urinary levels of a parathyroid hormone-related protein COOH terminus in non-small cell lung cancer patients. Clin. Cancer Res. 5, 1473–1481 (1995).
Dougherty, K. M., Blomme, E. A., Koh, A. J., Henderson, J. E., Pienta, K. J., Rosol, T. J. et al. Parathyroid hormone-related protein as a growth regulator of prostate carcinoma. Cancer Res. 59, 6015–6022 (1999).
Agouni, A., Sourbier, C., Danilin, S., Rothhut, S., Lindner, V., Jacqmin, D. et al. Parathyroid hormone-related protein induces cell survival in human renal cell carcinoma through the PI3K Akt pathway: evidence for a critical role for integrin-linked kinase and nuclear factor kappa B. Carcinogenesis 28, 1893–1901 (2007).
Nishihara, M., Ito, M., Tomioka, T., Ohtsuru, A., Taguchi, T. & Kanematsu, T. Clinicopathological implications of parathyroid hormone-related protein in human colorectal tumours. J. Pathol. 187, 217–222 (1999).
Alipov, G. K., Ito, M., Nakashima, M., Ikeda, Y., Nakayama, T., Ohtsuru, A. et al. Expression of parathyroid hormone-related peptide (PTHrP) in gastric tumours. J. Pathol. 182, 174–179 (1997).
Deftos, L. J., Barken, I., Burton, D. W., Hoffman, R. M. & Geller, J. Direct evidence that PTHrP expression promotes prostate cancer progression in bone. Biochem. Biophys. Res. Commun. 327, 468–472 (2005).
Firkin, F., Seymour, J. F., Watson, A. M., Grill, V. & Martin, T. J. Parathyroid hormone-related protein in hypercalcaemia associated with haematological malignancy. Br. J. Haematol. 94, 486–492 (1996).
Kissin, M. W., Henderson, M. A., Danks, J. A., Hayman, J. A., Bennett, R. C. & Martin, T. J. Parathyroid hormone related protein in breast cancers of widely varying prognosis. Eur. J. Surg. Oncol. 19, 134–142 (1993).
Kremer, R., Shustik, C., Tabak, T., Papavasiliou, V. & Goltzman, D. Parathyroid-hormone-related peptide in hematologic malignancies. Am. J. Med. 100, 406–411 (1996).
Rankin, W., Grill, V. & Martin, T. J. Parathyroid hormone-related protein and hypercalcemia. Cancer 80, 1564–1571 (1997).
Truong, N. U., de B Edwardes, M. D., Papavasiliou, V., Goltzman, D. & Kremer, R. Parathyroid hormone-related peptide and survival of patients with cancer and hypercalcemia. Am. J. Med. 115, 115–121 (2003).
Howe, E. N., Cochrane, D. R. & Richer, J. K. Targets of miR-200c mediate suppression of cell motility and anoikis resistance. Breast Cancer Res. 13, R45 (2011).
Uhlmann, S., Zhang, J. D., Schwäger, A., Mannsperger, H., Riazalhosseini, Y., Burmester, S. et al. miR-200bc/429 cluster targets PLCgamma1 and differentially regulates proliferation and EGF-driven invasion than miR-200a/141 in breast cancer. Oncogene 29, 4297–4306 (2010).
Sun, T., Wang, C., Xing, J. & Wu, D. miR-429 modulates the expression of c-myc in human gastric carcinoma cells. Eur. J. Cancer 47, 2552–2559 (2011).
Williams, K. C., Renthal, N. E., Condon, J. C., Gerard, R. D. & Mendelson, C. R. MicroRNA-200a serves a key role in the decline of progesterone receptor function leading to term and preterm labor. Proc. Natl. Acad. Sci. USA 109, 7529–7534 (2012).
Acknowledgements
This study was supported by the Ministry of Education, Sciences, Sports and Culture, and Grant-in-Aid for Science Research (C), 23501298 and 23592340. We thank Ms Mutsumi Miyazaki for her excellent laboratory assistance.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on Journal of Human Genetics website
Supplementary information
Rights and permissions
About this article
Cite this article
Yoshino, H., Enokida, H., Itesako, T. et al. Epithelial–mesenchymal transition-related microRNA-200s regulate molecular targets and pathways in renal cell carcinoma. J Hum Genet 58, 508–516 (2013). https://doi.org/10.1038/jhg.2013.31
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/jhg.2013.31
Keywords
This article is cited by
-
EHHADH contributes to cisplatin resistance through regulation by tumor-suppressive microRNAs in bladder cancer
BMC Cancer (2021)
-
Up-regulation of microRNA-200c-3p inhibits invasion and migration of renal cell carcinoma cells via the SOX2-dependent Wnt/β-catenin signaling pathway
Cancer Cell International (2019)
-
Circulating miR-200a is a novel molecular biomarker for early-stage renal cell carcinoma
ExRNA (2019)
-
Aberrantly expressed microRNAs in bladder cancer and renal cell carcinoma
Journal of Human Genetics (2017)
-
The putative tumor suppressor microRNA-30a-5p modulates clear cell renal cell carcinoma aggressiveness through repression of ZEB2
Cell Death & Disease (2017)